Overview of Hydromet

Hydromet is a synthetic, prescription-only medication classified as a fixed-dose combination antihypertensive agent administered via a single oral tablet. This pharmaceutical preparation is designed for the long-term management of high blood pressure (hypertension) in adult patients.

Quick Facts

Property	Description
Active Ingredients	Hydrochlorothiazide (HCTZ), Methyldopa
Form	Oral Tablet
Pharmacological Class	Antihypertensive (Diuretic-Sympatholytic Combination)
Common Use	Long-term management of hypertension
Origin	Synthetic

What Type of Medicine is Hydromet and What is it Made Of?

Hydromet is a combination drug that features the diuretic Hydrochlorothiazide and the centrally acting agent Methyldopa, placing it in the high-level pharmacological class of antihypertensive agents.

The core composition includes two distinct active ingredients [INN]. Hydrochlorothiazide is formally classified as a thiazide diuretic that promotes the excretion of excess water and sodium. Methyldopa is categorized as a centrally acting antiadrenergic agent that reduces nerve signals in the brainstem. The formulation as a fixed-dose combination is clinically recognized for promoting patient adherence and effective control in the treatment of established hypertension.

Hydrochlorothiazide and Methyldopa: A Dual-Action Combination

The combined action of Hydrochlorothiazide and Methyldopa addresses hypertension by simultaneously targeting fluid volume and central nervous system control. Hydrochlorothiazide reduces fluid volume within the bloodstream via natriuresis (sodium excretion), while Methyldopa works by decreasing the sympathetic outflow—the signals that prompt the constriction of blood vessels—from the central nervous system. This strategic pairing distinguishes the therapy from monotherapy treatments, where a single drug focuses solely on one mechanism.

What is the General Purpose of Hydromet Therapy?

The general purpose of Hydromet therapy is the long-term management of hypertension (high blood pressure) to reduce cardiovascular strain. This medication's ultimate goal is to ensure the heart and blood vessels operate under sustained lower pressures by mitigating the forces of both fluid retention and vessel constriction. The formulation is typically prescribed for adult patients when blood pressure control cannot be achieved by a single antihypertensive agent alone.

Regulatory References

National Library of Medicine, DailyMed: Hydrochlorothiazide

What side effects are possible with Hydromet?

Possible Side Effects and Safety Information

The official safety information for Hydromet (hydrocodone bitartrate and homatropine methylbromide) outlines serious risks, common adverse reactions, and specific limitations on use, strictly based on government regulatory documents.

Serious and Clinically Significant Risks

The medicine carries a risk of addiction, abuse, and misuse, which can lead to overdose and death. A primary safety concern is life-threatening respiratory depression (slowed or stopped breathing), a risk that is greatest when starting therapy or following a dose increase.

Accidental ingestion, particularly by children, can result in a fatal overdose of the hydrocodone component. Concomitant use with alcohol, benzodiazepines, or other Central Nervous System (CNS) depressants may result in profound sedation, respiratory depression, coma, and death. Interactions with CYP3A4 inhibitors or inducers may also significantly increase the risk of fatal adverse effects.

Common Adverse Reactions

The most frequently reported adverse reactions affect the nervous and gastrointestinal systems. These commonly include:

Sedation (somnolence, mental clouding, lethargy)
Impaired mental and physical performance
Lightheadedness, dizziness, headache
Dry mouth
Nausea, vomiting, and constipation

Contraindications and Safety Limitations

This medicine is contraindicated in children younger than 6 years of age due to the risk of fatal respiratory depression. It is also restricted for use in patients with significant respiratory issues, such as acute or severe bronchial asthma in an unmonitored setting, and in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.

Prolonged use during pregnancy may result in Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn. Patients with predisposing conditions such as severe hepatic or renal impairment, hypothyroidism, or a history of substance use disorder require particular caution and monitoring during treatment.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with the fixed-dose combination of Hydrochlorothiazide and Methyldopa (Hydromet) is officially documented to present with signs related to both component classes, requiring immediate emergency intervention.

Documented Manifestations and Severe Outcomes

Official prescribing information describes acute overdosage as potentially leading to profound hypotension and marked bradycardia from the Methyldopa component. The Hydrochlorothiazide component may result in severe fluid and electrolyte disturbances, specifically hypokalemia and hyponatremia, which can manifest as drowsiness, confusion, muscular fatigue, and excessive sedation.

Severity may escalate to life-threatening outcomes, including circulatory collapse, cardiac arrhythmias resulting from electrolyte imbalance, and seizures. In patients with pre-existing severe hepatic impairment, the thiazide component carries the specific risk of precipitating hepatic coma.

Required Emergency Actions

The regulatory guidance mandates that patients seek immediate medical attention for any suspected overdose. Urgent care is required if the affected individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Treatment is strictly symptomatic and supportive, as no specific antidote is known for the Methyldopa component. Supportive measures include necessary interventions such as gastric lavage, administration of activated charcoal, and correction of electrolyte imbalances (e.g., vigorous potassium replacement) under continuous hospital monitoring of vital signs and ECG.

Therapeutic Uses of Hydromet

Hydromet is indicated for the temporary symptomatic relief of cough in adult patients 18 years of age and older. This medication is reserved for use when the benefits of cough suppression are expected to outweigh the associated risks, and where an adequate assessment of the cough's origin has been made.

It is used to help manage persistent, severe, non-productive coughing episodes that can be disruptive to daily life. The therapeutic goal is to assist in reducing the frequency and intensity of cough. This relief is important for scenarios like nocturnal cough that interrupts normal sleep, thereby supporting improved rest and overall comfort. The approved uses are generally associated with common respiratory irritations and the common cold.

Quick Fact: Relief for Severe Cough (Hydromet is used to help manage symptomatic, severe, non-productive cough when simpler treatments have proven insufficient.)

“The primary use focuses on symptomatic cough relief in adults where the clinical need is established.”

Eligibility and Restrictions for Use

Who Can and Cannot Use Hydromet?

Hydromet (Methyldopa/Hydrochlorothiazide) is officially approved for the long-term management of hypertension in adult patients. Regulatory guidelines define specific populations who are prohibited from using the medicine or who require restricted use.

Contraindicated Populations (Must Not Use)

The medicine is absolutely prohibited for use in patients with active hepatic disease (including acute hepatitis or active cirrhosis), anuria, or a known hypersensitivity to either Methyldopa, Hydrochlorothiazide, or any sulfonamide-derived drug. Use is also strictly contraindicated for patients with a catecholamine-secreting tumor (e.g., pheochromocytoma) or those concurrently receiving Monoamine Oxidase (MAO) inhibitors.

Population Restrictions and Limitations

Pediatric Use: Safety and efficacy are not established in children under 18 years of age.
Organ Function: Use is not recommended in cases of severe renal impairment and requires caution with impaired hepatic function due to the risk of precipitating hepatic coma.
Comorbidities: Caution is required for patients with Systemic Lupus Erythematosus, Gout, or Diabetes Mellitus, as the medicine may exacerbate these underlying conditions.
Pregnancy/Lactation: It is a Pregnancy Category C drug, to be used only if the clinical need outweighs the potential risk. Both components are found in breast milk, requiring caution during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Hydromet (Methyldopa and Hydrochlorothiazide) is subject to specific, officially documented interaction patterns that are defined by government regulatory authorities.

Contraindicated Combinations and Exposure Modification

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is explicitly contraindicated due to the high documented risk of severe hypertensive reactions. The Hydrochlorothiazide component officially reduces the renal clearance of Lithium, which significantly increases the risk of Lithium toxicity and requires caution during co-administration.

Pharmacodynamic Effects and Timing Constraints

The combination with other Antihypertensive Drugs may result in an additive or potentiation of the blood pressure-lowering effect. Combining with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is documented to reduce the diuretic and antihypertensive effects of Hydrochlorothiazide. Furthermore, co-administration with Alcohol, Barbiturates, or Narcotics may potentiate the risk of orthostatic hypotension.

To ensure proper absorption, co-administration with Iron Supplements is restricted and requires a mandatory timing separation. The Hydrochlorothiazide component's absorption is also officially impaired by co-administration with Cholestyramine or Colestipol Resins.

Mechanism of Action

Hydromet operates at the cellular level by targeting the farnesyl pyrophosphate synthase (FPPS) enzyme within osteoclasts. The active compound is initially taken up by bone mineral, where its structural similarity to pyrophosphate facilitates selective accumulation. Upon internalization by the osteoclast, the drug binds to and inhibits FPPS. This enzyme is a critical component of the mevalonate pathway, which is responsible for producing isoprenoid lipids essential for the post-translational prenylation of specific signaling proteins. The inhibition of FPPS prevents the synthesis of these necessary lipids. This disruption results in a lack of prenylation for key small GTPases, such as Rac and Rho, which maintain the osteoclast's cytoskeletal structure and the formation of the ruffled border. The subsequent cytoskeletal collapse and loss of the ruffled border prevents the cell from secreting the required acids and enzymes. This mechanistic cascade leads to the functional inactivation and eventual apoptosis (programmed cell death) of the osteoclast, thereby modulating the rate of bone resorption activity at the tissue level.

Dosage and Administration Information

How to Use Hydromet

Administration and Dosage Rules

The fixed-dose combination of Methyldopa and Hydrochlorothiazide (HCTZ) is administered solely via the oral tablet route. This combination is not indicated for initial therapy of high blood pressure. It is reserved for replacement therapy after the optimal dosage of the individual components has been determined through prior, separate titration. Standard adult dosing is individualized, but generally involves the tablet being taken once daily or in two to three divided doses throughout the day. The maximum daily dose of the hydrochlorothiazide component should not exceed 50 mg.

Timing and Procedural Conditions

The last divided dose of the medication is generally recommended to be taken no later than 6:00 p.m. to minimize the diuretic effect of HCTZ on nighttime sleep. If taken as a single daily dose, it is typically administered in the morning. When a dosage adjustment is required, initiating the increase with the evening dose is a common practice to mitigate potential initial sedation associated with Methyldopa.

Use in Specific Populations

This medication is not approved for use in pediatric patients. Use is subject to explicit restrictions concerning organ function: the combination should be avoided in cases of severe renal impairment (CrCl < 30 mL/min) and is contraindicated in patients with active liver disease. If a dose is missed, it should be taken as soon as remembered, but a double dose must be avoided.

Recent Clinical Evidence

Hydromet: Recent Clinical Evidence

Clinical evidence for Hydromet, a combination medication typically containing hydrocodone and homatropine, primarily focuses on its efficacy as an antitussive (cough suppressant) agent. Its use is generally reserved for the relief of cough associated with mild respiratory tract infections or allergic conditions.

Efficacy and Study Focus

Clinical trials examining hydrocodone's antitussive action, the primary therapeutic component, have historically demonstrated that it can elevate the cough threshold. Recent research emphasis has shifted toward evaluating the risk-benefit profile, particularly concerning the opioid component (hydrocodone).

Research Focus	Study Design	Key Outcome Evaluated
Antitussive Efficacy	Placebo-controlled trials	Change in cough frequency and severity
Pharmacokinetics	Open-label studies	Absorption and metabolism of hydrocodone/homatropine
Safety and Abuse Potential	Post-marketing surveillance	Incidence of adverse events and misuse

Safety and Post-Marketing Data

Safety data consistently show that the most common adverse events reported in patients using hydrocodone combination products include dizziness, sedation, and nausea. The inclusion of a small, sub-therapeutic dose of homatropine is intended to act as a deterrent to misuse or abuse of the hydrocodone component, although evidence regarding its definitive effectiveness as a deterrent is complex and subject to ongoing review. Due to the presence of an opioid, clinical guidelines stress the importance of using Hydromet only when necessary and for the shortest duration possible to manage acute symptoms.

Key Studies & References

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE Oral Solution (HYDROMET) - DailyMed

How should Hydromet be stored and disposed of?

How to Store and Dispose of Hydromet

The storage and disposal instructions for Hydromet (hydrocodone bitartrate and homatropine methylbromide) oral solution are defined by regulatory labeling.

Storage Requirements

Hydromet must be stored at a Controlled Room Temperature between 20°C to 25°C (68°F to 77°F). The container must be kept tightly closed and protected from freezing, excessive heat, moisture, and light. Due to the presence of an opioid, it is mandatory to keep this medicine out of the reach of children and pets to prevent accidental, potentially fatal ingestion.

Disposal Instructions

Unused or expired Hydromet should be disposed of promptly. The preferred method is using an official drug take-back program. If a take-back program is not readily available, the FDA recommends flushing the unused medicine down the toilet immediately to prevent accidental access and misuse. Do not keep outdated medicine.

Hydromet